A Study to Investigate the Effect of Itraconazole on the Way the Body Absorbs, Distributes, and Gets Rid of ACT-1004-1239 Given as a Single Dose of 10 mg to Healthy Male Subjects

Phase 1 Completed 16 enrolled Idorsia Pharmaceuticals Ltd.

NaSingle-groupOpen-labelOther

Summary

A study to investigate the effect of itraconazole on the way the body absorbs, distributes, and gets rid of ACT-1004-1239 given as a single dose of 10 mg to healthy male subjects

Timeline

Start: 2022-10-01
Primary completion: 2022-10-20
Completion: 2022-10-20

Publications

Huynh C, Dingemanse J, Meyer Zu Schwabedissen HE, Fonseca M, Sidharta PN. The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first-in-class ACKR3/CXCR7 antagonist, ACT-1004-1239. Clin Transl Sci. 2024 Jul;17(7):e13883. doi: 10.1111/cts.13883.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ACT-1004-1239	Unknown	10 mg	Oral
Subject	Itraconazole	Small molecule	200 mg	Oral

Indications

No indication recorded.